Gilead And Arcus Biosciences Establish 10-Year Partnership To Co-Develop And Co-Commercialize Next-Generation Cancer Immunotherapies; Arcus To Receive $175M Up Front And $200M Equity Investment Plus Up To $1.6B In Potential R&D Funding+Milestones
Benzinga Newsdesk